CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $115.08M, lower than 95% of all stocks globally
- PositionReturn on assets is -85.3%, lower than 95% of its Biotechnology peers (median -20.1%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
85.21MGBP115.08M · vs all stocks (USD)
Revenue (TTM)
1.12MGBP1.52M · vs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.12xvs all stocks
52-Week Change
-77.30%vs all stocks
Market Capitalization
85.21MGBP115.08M · vs all stocks (USD)
Enterprise Value
51.85MGBP70.02M · vs all stocks (USD)
Forward P/E
-4.46xvs Biotechnology peers
Price to Sales (TTM)
65.15xvs Biotechnology peers
Enterprise to Revenue
46.19xvs Biotechnology peers
Enterprise to EBITDA
-3.01xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-638.99%vs Biotechnology peers
Return on Assets (TTM)
-85.32%vs Biotechnology peers
Revenue (TTM)
1.12MGBP1.52M · vs all stocks (USD)
Revenue per Share (TTM)
0.0120GBPUpdated Aug 1, 2026Gross Profit (TTM)
1.12MGBP1.52M · vs all stocks (USD)
EBITDA (TTM)
-17.20MGBP-23.24M · vs all stocks (USD)
Net Income (TTM)
-23.39MGBP-31.59M · vs all stocks (USD)
Operating Cash Flow (TTM)
-15.38MGBP-20.77M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-9.73MGBP-13.14M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00GBPUpdated Aug 1, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00EURFY2025 · Dec 31, 2025Operating Income
-18.96MEUR-21.88M · vs all stocks (USD)
Pre-tax Income
-27.25MEURFY2025 · Dec 31, 2025Income Tax Expense
2.00KEURFY2025 · Dec 31, 2025Net Income
-27.26MEURFY2025 · Dec 31, 2025EBIT
-25.98MEURFY2025 · Dec 31, 2025EBITDA (Income Statement)
-23.28MEURFY2025 · Dec 31, 2025Research & Development
12.65MEURFY2025 · Dec 31, 2025Selling, General & Administrative
2.83MEURFY2025 · Dec 31, 2025Non-operating Interest Income
56.00KEURFY2025 · Dec 31, 2025Non-operating Interest Expense
1.27MEURFY2025 · Dec 31, 2025EPS (Basic)
-0.2400EURFY2025 · Dec 31, 2025EPS (Diluted)
-0.2400EURFY2025 · Dec 31, 2025Basic Shares Outstanding
111.72MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
111.72MSharesFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00EURFY2025 · Dec 31, 2025Operating Cash Flow
-15.77MEURFY2025 · Dec 31, 2025Free Cash Flow
-15.77MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
12.32MEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-27.25MEURFY2025 · Dec 31, 2025Stock-based Compensation
1.82MEURFY2025 · Dec 31, 2025Other Non-cash Items
8.19MEURFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
1.47MEURFY2025 · Dec 31, 2025Capital Expenditures
0.00EURFY2025 · Dec 31, 2025Net Intangibles (CF)
-222.00KEURFY2025 · Dec 31, 2025Net Investing Cash Flow
0.00EURFY2025 · Dec 31, 2025Long-term Debt Issuance
25.00MEURFY2025 · Dec 31, 2025Long-term Debt Payments
-8.89MEURFY2025 · Dec 31, 2025Other Financing Charges
-6.24MEURFY2025 · Dec 31, 2025Net Financing Cash Flow
21.99MEURFY2025 · Dec 31, 2025Shares Outstanding
124.41MSharesUpdated Aug 1, 2026Float Shares
77.49MSharesUpdated Aug 1, 2026% Held by Insiders
16.44%vs all stocks
% Held by Institutions
20.64%vs all stocks
Total Cash (MRQ)
10.57MGBP14.28M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1080GBPUpdated Aug 1, 2026Total Debt (MRQ)
21.18MGBP28.60M · vs all stocks (USD)
Current Ratio (MRQ)
0.8380xvs Biotechnology peers
Book Value per Share (MRQ)
-0.1388GBPUpdated Aug 1, 2026Total Assets
17.17MEUR19.82M · vs all stocks (USD)
Total Current Assets
15.82MEURFY2025 · Dec 31, 2025Total Liabilities
35.68MEURFY2025 · Dec 31, 2025Total Non-current Assets
1.35MEURFY2025 · Dec 31, 2025Total Non-current Liabilities
16.80MEURFY2025 · Dec 31, 2025Total Current Liabilities
18.87MEURFY2025 · Dec 31, 2025Cash
12.32MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
12.32MEURFY2025 · Dec 31, 2025Accounts Payable
5.54MEURFY2025 · Dec 31, 2025Short-term Debt
10.40MEURFY2025 · Dec 31, 2025Long-term Debt
14.28MEURFY2025 · Dec 31, 2025Common Stock (Book)
2.69MEURFY2025 · Dec 31, 2025Retained Earnings
-222.86MEURFY2025 · Dec 31, 2025Total Shareholders' Equity
-18.51MEUR-21.36M · vs all stocks (USD)
52-Week Low
38.00GBXUpdated Aug 1, 202652-Week High
240.00GBXUpdated Aug 1, 202652-Week Change
-77.30%vs all stocks
Beta
1.12xvs all stocks
50-Day MA
42.87GBXUpdated Aug 1, 2026200-Day MA
97.51GBXUpdated Aug 1, 2026Avg 10-Day Volume
111.42KSharesUpdated Aug 1, 2026Avg 30-Day Volume
66.57KSharesUpdated Aug 1, 2026Diluted EPS (TTM)
-0.1900GBPUpdated Aug 1, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on assets is -85.3%, lower than 95% of its Biotechnology peers (median -20.1%)Significant
Return on assets: -0.85Industry median: -0.20Industry P5: -0.85Peers compared: 261
Current ratio is 0.84×, lower than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 0.84Industry median: 5.64Industry P5: 1.06Peers compared: 261
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.53
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $115.08M, lower than 95% of all stocks globallySignificant
Market cap (USD): 115,078,866.986Global P5: 269,387,740.27
Revenue is $1.52M, lower than 95% of all stocks globallySignificant
Revenue (USD): 1,515,933.461Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Engene Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRule
Polaryx Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Y-Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Nibec Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cellbion Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
PepGen Inc.
Tier 1ProductionApproval-Gated PipelineRule
3Billion Inc.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
CVRx, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pyridam Farma Tbk.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Bonus BioGroup Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Neuromeka Co., Ltd.
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shanghai Geoharbour Construction Group Co. Ltd.
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated